---
title: "LL-37"
canonical_url: https://peptidelibrary.app/library/ll-37
description: "Human host-defense peptide (cathelicidin) with antimicrobial and immunomodulatory activity. Not FDA-approved as a drug; excess LL-37 is implicated in rosacea/psoriasis biology."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# LL-37

LL-37 (also called Cathelicidin or hCAP18 fragment) is a research peptide in the Cathelicidin class. LL-37 is the only human cathelicidin, released by proteolytic cleavage of the hCAP18 precursor stored in neutrophil granules and produced by epithelial cells.

Human host-defense peptide (cathelicidin) with antimicrobial and immunomodulatory activity. Not FDA-approved as a drug; excess LL-37 is implicated in rosacea/psoriasis biology.

Also known as: Cathelicidin, hCAP18 fragment, CAP-18.

Categories: Cosmetic, Experimental.

## Classification

- Type: Human cathelicidin / research
- Mechanism class: Cathelicidin
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

LL-37 is the only human cathelicidin, released by proteolytic cleavage of the hCAP18 precursor stored in neutrophil granules and produced by epithelial cells. It folds into an amphipathic helix with cationic and hydrophobic faces on opposite sides, which lets it bind the anionic surface of bacterial membranes and permeabilise them — a physical mechanism that makes classical resistance difficult. Beyond direct antimicrobial action it is an immune signalling molecule: it neutralises lipopolysaccharide, modulates Toll-like receptor responses, and promotes chemotaxis and wound angiogenesis. Its transcription is driven by vitamin D through a response element in the CAMP gene promoter, which links vitamin D status to innate immune capacity. Sustained overexpression is proinflammatory and has been implicated in rosacea and psoriasis.

Targets: Microbial membranes, Innate immune receptors.

Origin: C-terminal fragment of hCAP18.

## Properties

- Sequence: LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
- Length: 37
- Molecular formula: C205H340N60O53
- Molecular weight: 4,493 g/mol
- CAS number: 154947-66-7
- Half-life: ~1-2 hours
- Studied routes: Topical, Intratumoral, Oral

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 2
- Preclinical sources: 0
- Latest source: 2023

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial. Wound Repair Regen. 2021. 2021. Controlled human trial. Population: 148 patients with hard-to-heal venous leg ulcers, mean age 67.6 years. Wound healing. The primary analysis found no significant improvement over placebo; a post-hoc subgroup with wounds of at least 10 cm2 did show improvement. Both strengths were safe and well tolerated. [Source](https://pubmed.ncbi.nlm.nih.gov/34687253/)
2. Efficacy of LL-37 cream in enhancing healing of diabetic foot ulcer: a randomized double-blind controlled trial. Arch Dermatol Res. 2023. 2023. Controlled human trial. Population: Adults with diabetic foot ulcer with mild infection. Granulation index improved consistently versus placebo. IL-1 alpha, TNF-alpha and aerobic bacterial colonisation were not significantly reduced. [Source](https://pubmed.ncbi.nlm.nih.gov/37480520/)
3. NCT04098562 — Efficacy of LL-37 Cream on Bacteria Colonization, Inflammation Response and Wound Healing in Diabetic Foot Ulcer. Human study (early or uncontrolled). Population: Planned 40 participants with diabetic foot ulcer. Bacterial colonisation, inflammation response and wound healing. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT04098562)
4. Dermatologic toxicity from novel therapy using antimicrobial peptide LL-37 in melanoma: A detailed examination of the clinicopathologic features. J Cutan Pathol. 2018. 2018. Human study (early or uncontrolled). Population: Patient with stage IIIC cutaneous melanoma, within a phase 1 trial of intratumoral LL-37. Injected lesions shrank. Widespread verrucous and keratoacanthoma-like skin lesions developed around day 45 and resolved within 2 months of stopping treatment. [Source](https://pubmed.ncbi.nlm.nih.gov/29665030/)
5. Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial. J Med Virol. 2023. 2023. Human study (early or uncontrolled). Population: 238 adult inpatients with Omicron BA.5.1.3 infection. Shorter time to SARS-CoV-2 RNA negative conversion (9.80 vs 14.04 days) when started within 6 days. No severe adverse events reported. Research on a related compound, not this one. Limitations: Studied an analog, not LL-37 itself [Source](https://pubmed.ncbi.nlm.nih.gov/37605995/)

### Registered trials

- [NCT04098562](https://clinicaltrials.gov/study/NCT04098562)

## Safety

Side effects: Proinflammatory at high local levels; Cytotoxicity in vitro at high dose.

Risks: Not an approved antibiotic.

Contraindications: Autoimmune flares.

Human safety basis: Limited human reports

Key limitations: Not approved by the FDA for any use..

## Regulatory status

LL-37 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- Availability: Research-Only

## Frequently asked questions

### What is LL-37?

Human host-defense peptide (cathelicidin) with antimicrobial and immunomodulatory activity. Not FDA-approved as a drug; excess LL-37 is implicated in rosacea/psoriasis biology.

### How does LL-37 work?

LL-37 is the only human cathelicidin, released by proteolytic cleavage of the hCAP18 precursor stored in neutrophil granules and produced by epithelial cells. It folds into an amphipathic helix with cationic and hydrophobic faces on opposite sides, which lets it bind the anionic surface of bacterial membranes and permeabilise them — a physical mechanism that makes classical resistance difficult.

### Is LL-37 FDA approved?

No. LL-37 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use. FDA's compounding lists show 503A nomination: Previously in Category 2; nomination withdrawn by the nominators.

### What is the half-life of LL-37?

Reported half-life for LL-37 is ~1-2 hours. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of LL-37?

LL-37 has the sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES. Its molecular formula is C205H340N60O53.

### What peptides are similar to LL-37?

Compounds most often compared with LL-37 include KPV, Thymosin Alpha-1, Tuftsin and Bonomarlot. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Human cathelicidin antimicrobial protein 18 (hCAP18/LL-37) is increased in foetal membranes and myometrium after spontaneous labour and delivery — J Reprod Immunol, 2015](https://pubmed.ncbi.nlm.nih.gov/25435436/)
- [Role of antimicrobial peptide cathelicidin in thrombosis and thromboinflammation — Front Immunol, 2023](https://pubmed.ncbi.nlm.nih.gov/37090695/)
- [Antibiofilm properties of cathelicidin LL-37: an in-depth review — World J Microbiol Biotechnol, 2023](https://pubmed.ncbi.nlm.nih.gov/36781570/)
- [The LL-37 domain: A clue to cathelicidin immunomodulatory response? — Peptides, 2023](https://pubmed.ncbi.nlm.nih.gov/37068711/)
- [Renovation as innovation: Repurposing human antibacterial peptide LL-37 for cancer therapy — Front Pharmacol, 2022](https://pubmed.ncbi.nlm.nih.gov/36081952/)
